Taiwan
· Delayed Price · Currency is TWD Intech Biopharm Statistics
Total Valuation
Intech Biopharm has a market cap or net worth of TWD 4.05 billion. The enterprise value is 5.06 billion.
| Market Cap | 4.05B |
| Enterprise Value | 5.06B |
Important Dates
The next estimated earnings date is Friday, November 8, 2024.
| Earnings Date | Nov 8, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Intech Biopharm has 137.41 million shares outstanding. The number of shares has increased by 12.23% in one year.
| Shares Outstanding | 137.41M |
| Shares Change (YoY) | +12.23% |
| Shares Change (QoQ) | +0.01% |
| Owned by Insiders (%) | 1.26% |
| Owned by Institutions (%) | 1.93% |
| Float | 74.11M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 119.47 |
| PB Ratio | 4.03 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -14.39 |
| EV / Sales | 156.72 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -17.76 |
Financial Position
The company has a current ratio of 1.48, with a Debt / Equity ratio of 142.75.
| Current Ratio | 1.48 |
| Quick Ratio | 1.20 |
| Debt / Equity | 142.75 |
| Debt / EBITDA | n/a |
| Debt / FCF | -5.04 |
| Interest Coverage | -9.78 |
Financial Efficiency
Return on equity (ROE) is -37.26% and return on invested capital (ROIC) is -8.71%.
| Return on Equity (ROE) | -37.26% |
| Return on Assets (ROA) | -8.32% |
| Return on Capital (ROIC) | -8.71% |
| Revenue Per Employee | 393,634 |
| Profits Per Employee | -4.29M |
| Employee Count | 82 |
| Asset Turnover | 0.01 |
| Inventory Turnover | 4.07 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +7.16% in the last 52 weeks. The beta is 0.34, so Intech Biopharm's price volatility has been lower than the market average.
| Beta (5Y) | 0.34 |
| 52-Week Price Change | +7.16% |
| 50-Day Moving Average | 29.27 |
| 200-Day Moving Average | 28.49 |
| Relative Strength Index (RSI) | 50.55 |
| Average Volume (20 Days) | 294,391 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Intech Biopharm had revenue of TWD 32.28 million and -351.58 million in losses. Loss per share was -2.69.
| Revenue | 32.28M |
| Gross Profit | -161.14M |
| Operating Income | -334.97M |
| Pretax Income | -351.58M |
| Net Income | -351.58M |
| EBITDA | -249.83M |
| EBIT | -334.97M |
| Loss Per Share | -2.69 |
Balance Sheet
The company has 429.37 million in cash and 1.43 billion in debt, giving a net cash position of -1.00 billion or -7.31 per share.
| Cash & Cash Equivalents | 429.37M |
| Total Debt | 1.43B |
| Net Cash | -1.00B |
| Net Cash Per Share | -7.31 |
| Equity (Book Value) | 1.00B |
| Book Value Per Share | 7.31 |
| Working Capital | 178.26M |
Cash Flow
In the last 12 months, operating cash flow was -228.04 million and capital expenditures -56.74 million, giving a free cash flow of -284.78 million.
| Operating Cash Flow | -228.04M |
| Capital Expenditures | -56.74M |
| Free Cash Flow | -284.78M |
| FCF Per Share | -2.07 |
Margins
| Gross Margin | n/a |
| Operating Margin | -1,037.75% |
| Pretax Margin | -1,089.22% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | -882.27% |
Dividends & Yields
Intech Biopharm does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -12.23% |
| Shareholder Yield | -12.23% |
| Earnings Yield | -9.12% |
| FCF Yield | -7.03% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |